Narodowy Fundusz Zdrowia - Terapie CAR-T
공공데이터포털
,Raport przedstawia dane w zakresie realizacji świadczeń terapii CAR-T w ramach programów lekowych leczenia białaczki limfoblastycznej oraz chłoniaków B-komórkowych,,Terapia CAR-T jest zaawansowaną formą immunoterapii komórkowej, która znajduje zastosowanie m.in. w terapii nowotworów hematologicznych. Od września 2021 r. jest refundowana w ramach programu lekowego leczenia chorych na ostrą białaczkę limfoblastyczną, a od maja 2022 r. w ramach programu lekowego leczenia chorych na chłoniaki B-komórkowe.,,Zgodnie z danymi NFZ, do końca czerwca 2023 r. sprawozdano w Polsce terapię CAR-T dla 83 pacjentów. Łączna sprawozdana wartość refundacji terapii wyniosła 115,2 mln zł.,W raporcie przeczytasz o:,- liczbie pacjentów z zastosowaną terapią CAR-T w danym wskazaniu,,- wartości refundacji sprawozdanych podań leków w ramach terapii CAR-T,,- świadczeniodawcach realizujących świadczenia związane z terapią CAR-T,,- śmiertelności pacjentów z zastosowaną terapią CAR-T oraz częstości występowania CRS (zespołu uwalniania cytokin).,
Perturbations in the impact of mutational activity on Vλ genes in systemic lupus erythematosus
공공데이터포털
To assess the impact of somatic hypermutation and selective influences on the Vλ light chain repertoire in systemic lupus erythematosus (SLE), the frequency and pattern of mutations were analyzed in individual CD19+ B cells from a patient with previously undiagnosed SLE. The mutational frequency of nonproductive and productive rearrangements in the SLE patient was greater (3.1 × 10-2 vs 3.4 × 10-2, respectively) than that in normal B cells (1.2 × 10-2 vs 2.0 × 10-2, both P < 0.001). The frequencies of mutated rearrangements in both the nonproductive and productive repertoires were significantly higher in the patient with SLE than in normal subjects. Notably, there were no differences in the ratio of replacement to silent (R/S) mutations in the productive and nonproductive repertoires of the SLE patient, whereas the R/S ratio in the framework regions of productive rearrangements of normal subjects was reduced, consistent with active elimination of replacement mutations in this region. The pattern of mutations was abnormal in the SLE patient, with a significant increase in the frequency of G mutations in both the productive and nonproductive repertoires. As in normal subjects, however, mutations were found frequently in specific nucleotide motifs, the RGYW/WRCY sequences, accounting for 34% (nonproductive) and 46% (productive) of all mutations. These data are most consistent with the conclusion that in this SLE patient, the mutational activity was markedly greater than in normal subjects and exhibited some abnormal features. In addition, there was decreased subsequent positive or negative selection of mutations. The enhanced and abnormal mutational activity along with disturbances in selection may play a role in the emergence of autoreactivity in this patient with SLE.
K Saili Molecular characterization of a toxicological tipping point during human stem cell differentiation
공공데이터포털
We differentiated human induced pluripotent stem cells (hiPSCs) to embryonic endoderm and sought to identify a tipping point at which the developing system did not recover from perturbations caused by exposure to a known teratogen, all-trans retinoic acid (ATRA). Differentiating iPSC-derived endoderm was exposed to five concentrations of ATRA between 0.001 and 10 µM at 6h, 96h, or 192h and assessed for forkhead box A2 (FOXA2) protein expression and global gene transcript expression measured by RNA-sequencing. A tipping point of 17±11 nM was identified where patterns of differentially expressed genes supported a shift in the developmental trajectory away from embryonic endoderm in favor of mesoderm and extraembryonic endoderm. Five concentrations of all-trans retinoic acid (ATRA) between 0.001 and 10 µM were compared to time-matched 0.1% DMSO controls at three timepoints (6h, 96h, and 192h) in differentiating endoderm. Two biological replicates were used. Undifferentiated controls (not in DMSO) were also included in duplicate as internal controls for 6h, 96h, and 144h. This dataset is associated with the following publication: Saili, K., T. Antonijevic, T. Zurlinden, I. Shah, C. Deisenroth, and T. Knudsen. Molecular characterization of a toxicological tipping point during human stem cell differentiation. REPRODUCTIVE TOXICOLOGY. Elsevier Science Ltd, New York, NY, USA, 91(January 2020): 1-13, (2020).
Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons
공공데이터포털
Background BMP-5 is expressed in the nervous system throughout development and into adulthood. However its effects on neural tissues are not well defined. BMP-5 is a member of the 60A subgroup of BMPs, other members of which have been shown to stimulate dendritic growth in central and peripheral neurons. We therefore examined the possibility that BMP-5 similarly enhances dendritic growth in cultured sympathetic neurons. Results Sympathetic neurons cultured in the absence of serum or glial cells do not form dendrites; however, addition of BMP-5 causes these neurons to extend multiple dendritic processes, which is preceded by an increase in phosphorylation of the Smad-1 transcription factor. The dendrite-promoting activity of BMP-5 is significantly inhibited by the BMP antagonists noggin and follistatin and by a BMPR-IA-Fc chimeric protein. RT-PCR and immunocytochemical analyses indicate that BMP-5 mRNA and protein are expressed in the superior cervical ganglia (SCG) during times of initial growth and rapid expansion of the dendritic arbor. Conclusions These data suggest a role for BMP-5 in regulating dendritic growth in sympathetic neurons. The signaling pathway that mediates the dendrite-promoting activity of BMP-5 may involve binding to BMPR-IA and activation of Smad-1, and relative levels of BMP antagonists such as noggin and follistatin may modulate BMP-5 signaling. Since BMP-5 is expressed at relatively high levels not only in the developing but also the adult nervous system, these findings suggest the possibility that BMP-5 regulates dendritic morphology not only in the developing, but also the adult nervous system.